Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt… - Supportive Care in …, 2006 - Springer
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg… - … Care in Cancer, 2006 - einstein.elsevierpure.com
Goals of work: Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Combined data from two phase III trials of the NK^ sub 1^ antagonist aprepitant plus a 5HT^ sub 3^ antagonist and a corticosteroid for prevention of chemotherapy …
PJ Hesketh, SM Grunberg, J Herrstedt… - Supportive Care in …, 2006 - search.proquest.com
Prevention of chemotherapy-induced nausea and vomiting (CINV) with standard antiemetics
has been more difficult to achieve in female patients. Data from two phase III trials of the NK …
has been more difficult to achieve in female patients. Data from two phase III trials of the NK …
[引用][C] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced …
PJ Hesketh, SM Grunberg, J Herrstedt… - Supportive Care in …, 2006 - cir.nii.ac.jp
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist
and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of …
and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt… - Supportive Care in …, 2006 - europepmc.org
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt, R de Wit… - 2006 - pubmed.ncbi.nlm.nih.gov
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
[PDF][PDF] Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced …
JK Evans, KJ Horgan - Support Care Cancer, 2006 - academia.edu
Goals of work: Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
P Hesketh, S Grunberg, J Herrstedt, R de Wit… - Supportive Care in …, 2006 - repub.eur.nl
Goals of work: Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …
Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea …
PJ Hesketh, SM Grunberg, J Herrstedt, R Wit… - Supportive Care in …, 2006 - infona.pl
Goals of work Prevention of chemotherapy-induced nausea and vomiting (CINV) with
standard antiemetics has been more difficult to achieve in female patients. Data from two …
standard antiemetics has been more difficult to achieve in female patients. Data from two …